Business Context and Reporting Period
This Form 6-K filing by Inventiva S.A. covers the month of June 2026, specifically detailing a comprehensive refinancing transaction announced on June 1 and June 2, 2026. The transaction, termed the "Combined Transaction," involves a new equity offering, the repayment of existing European Investment Bank (EIB) debt, and a new secured debt facility with BlackRock and Claret Capital Partners.
Key Financial Metrics and Transaction Details
Equity Offering
- Shares Issued: 27,272,727 new American Depositary Shares (ADSs).
- Offering Price: $4.40 per ADS.
- Net Proceeds: Approximately $110.8 million (€95.2 million) after underwriting commissions and expenses.
- Closing Date: Expected June 5, 2026.
Debt Financing (New Facility)
- Total Commitment: Up to €130 million in committed tranches plus an uncommitted tranche of up to €20 million.
- Initial Drawdown: €75 million (Tranches A and B).
- Tranche A (Convertible): Up to €35 million; 9.90% annual fixed interest; convertible into Ordinary Shares.
- Tranche B (Amortized): Up to €40 million; 9.90% annual fixed interest plus 2.10% PIK interest.
- Tranche C (Amortized): Up to €55 million; 8.90% annual fixed interest plus 2.10% PIK interest; subject to clinical and equity milestones.
- Lenders' Warrants: Warrants exercisable for up to €6.75 million of shares (Tranches A/B) and €2.75 million (Tranche C).
Debt Repayment (EIB Transactions)
- Outstanding EIB Loan: Approximately €63 million (principal and accrued interest) as of June 2, 2026.
- Warrant Repurchase: Company to repurchase and cancel EIB warrants for €50 million (approx. 40% discount to intrinsic value).
- Loan Repayment: Full prepayment of the EIB Loan, with early prepayment fees waived.
Liquidity and Covenants
- Cash Covenant: Company must maintain at least €30.0 million in cash and cash equivalents in specified secured accounts.
- Debt-to-Market Cap: Tranche C availability is subject to a maximum debt-to-market capitalization ratio of 10%.
Material Changes Versus Prior Period
The filing does not provide comparative financial statements (revenue, profit, or cash flow) for the prior period. However, it details significant structural changes to the company's capitalization:
- Debt Restructuring: Replacement of the existing EIB loan (€63 million outstanding) with a new €130 million facility from private lenders.
- Equity Dilution: Issuance of 27.3 million new ADSs and potential issuance of new warrants to the EIB and new lenders.
- Warrant Mitigation: Elimination of anti-dilution provisions and put options associated with the existing EIB warrants, which previously posed a dilution risk exceeding 10% of share capital.
Guidance, Outlook, Risks, and Contingencies
Management Commentary and Outlook
The transaction is designed to provide liquidity to support the development of NATiV3 (lanifibranor) for MASH. The company expects the Combined Transaction to close in mid-June 2026, subject to customary conditions and shareholder approval for new EIB warrants by October 31, 2026.
Key Risks and Contingencies
- Clinical Trial Default: Failure to achieve the primary composite endpoint in the NATiV3 Phase 3 clinical trial constitutes an event of default, subject to cure mechanics involving secondary endpoints and the exercise of T3 warrants.
- Regulatory Risk: Adverse regulatory outcomes for the NATiV3 New Drug Application (NDA) are events of default.
- Market Capitalization Triggers: If the outstanding principal of Tranches A and B exceeds 10% of post-results market capitalization, lenders may require prepayment. If market cap falls below €400 million post-cure, full repayment may be required.
- Shareholder Approval: Issuance of New EIB Warrants requires shareholder approval. If not obtained by October 31, 2026, the EIB retains remaining warrants, and waivers of anti-dilution rights may be withdrawn retroactively if the transaction fails.
- Restrictive Covenants: The new debt agreement includes restrictions on indebtedness, asset disposals, dividends, and mergers.
Important Facts for Investor Verification
- Verify the closing of the $110.8 million equity offering and the receipt of net proceeds.
- Confirm the full repayment of the €63 million EIB loan and the successful repurchase of EIB warrants for €50 million.
- Monitor the drawdown of the initial €75 million from the BlackRock/Claret facility and the satisfaction of conditions for Tranche C (Phase 3 results and T3 warrant exercise).
- Track the outcome of the shareholder meeting expected on June 30, 2026, regarding the issuance of New EIB Warrants.
- Review the company's ability to maintain the €30 million cash covenant and the 10% debt-to-market cap ratio.
- Assess the impact of the new debt covenants on future financing flexibility, particularly regarding the NATiV3 Phase 3 trial results.